| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypoplastic Left Heart Syndrome | 19 | 2025 | 269 | 5.090 |
Why?
|
| Marfan Syndrome | 16 | 2025 | 124 | 4.610 |
Why?
|
| Heart Defects, Congenital | 37 | 2025 | 1843 | 4.520 |
Why?
|
| Loeys-Dietz Syndrome | 12 | 2025 | 40 | 4.160 |
Why?
|
| Echocardiography | 24 | 2025 | 1098 | 3.160 |
Why?
|
| Ultrasonography, Prenatal | 22 | 2025 | 999 | 3.060 |
Why?
|
| Fetal Heart | 13 | 2025 | 135 | 2.900 |
Why?
|
| Turner Syndrome | 7 | 2022 | 45 | 2.270 |
Why?
|
| Ehlers-Danlos Syndrome | 6 | 2025 | 48 | 1.970 |
Why?
|
| Skin Diseases, Genetic | 6 | 2025 | 20 | 1.770 |
Why?
|
| Joint Instability | 6 | 2025 | 57 | 1.720 |
Why?
|
| Arteries | 6 | 2025 | 198 | 1.640 |
Why?
|
| Vascular Malformations | 6 | 2025 | 107 | 1.610 |
Why?
|
| Aorta | 10 | 2025 | 500 | 1.550 |
Why?
|
| Aortic Aneurysm, Thoracic | 11 | 2025 | 542 | 1.510 |
Why?
|
| Aortic Valve | 10 | 2024 | 412 | 1.510 |
Why?
|
| Pregnancy | 36 | 2025 | 7404 | 1.410 |
Why?
|
| Aorta, Thoracic | 10 | 2025 | 465 | 1.360 |
Why?
|
| Retrospective Studies | 62 | 2025 | 16770 | 1.360 |
Why?
|
| Transposition of Great Vessels | 5 | 2021 | 118 | 1.340 |
Why?
|
| Hospital Mortality | 13 | 2024 | 976 | 1.340 |
Why?
|
| Female | 114 | 2026 | 67915 | 1.290 |
Why?
|
| Scimitar Syndrome | 2 | 2021 | 52 | 1.260 |
Why?
|
| Aortic Diseases | 5 | 2025 | 162 | 1.220 |
Why?
|
| Humans | 159 | 2026 | 126089 | 1.210 |
Why?
|
| Heart Septal Defects, Atrial | 4 | 2025 | 126 | 1.200 |
Why?
|
| Heart Ventricles | 12 | 2024 | 756 | 1.200 |
Why?
|
| Mitral Valve Insufficiency | 3 | 2025 | 179 | 1.180 |
Why?
|
| Infant Mortality | 8 | 2024 | 177 | 1.170 |
Why?
|
| Cardiac Catheterization | 7 | 2025 | 620 | 1.110 |
Why?
|
| Heart Valve Diseases | 8 | 2024 | 165 | 1.110 |
Why?
|
| Heart Transplantation | 8 | 2023 | 863 | 1.060 |
Why?
|
| Infant, Newborn | 36 | 2024 | 8358 | 1.050 |
Why?
|
| Aortic Stenosis, Supravalvular | 2 | 2024 | 20 | 1.050 |
Why?
|
| Child | 60 | 2025 | 25062 | 1.050 |
Why?
|
| Premature Birth | 2 | 2022 | 415 | 1.030 |
Why?
|
| Mitral Valve | 4 | 2024 | 248 | 1.020 |
Why?
|
| Cardiac Surgical Procedures | 9 | 2024 | 1125 | 0.990 |
Why?
|
| Heterotaxy Syndrome | 3 | 2024 | 53 | 0.960 |
Why?
|
| Infant | 44 | 2025 | 12762 | 0.950 |
Why?
|
| Atrial Septum | 1 | 2025 | 19 | 0.940 |
Why?
|
| Male | 85 | 2026 | 62089 | 0.900 |
Why?
|
| Gestational Age | 10 | 2025 | 1198 | 0.900 |
Why?
|
| Adolescent | 48 | 2025 | 19936 | 0.890 |
Why?
|
| Registries | 17 | 2024 | 1477 | 0.890 |
Why?
|
| Aortic Valve Stenosis | 3 | 2025 | 318 | 0.860 |
Why?
|
| Prenatal Diagnosis | 6 | 2023 | 627 | 0.860 |
Why?
|
| Cor Triatriatum | 1 | 2024 | 10 | 0.860 |
Why?
|
| Child, Preschool | 38 | 2025 | 14329 | 0.850 |
Why?
|
| Williams Syndrome | 1 | 2024 | 41 | 0.840 |
Why?
|
| Ventricular Function, Left | 4 | 2024 | 510 | 0.840 |
Why?
|
| Tetralogy of Fallot | 6 | 2021 | 173 | 0.830 |
Why?
|
| Stroke Volume | 3 | 2024 | 494 | 0.790 |
Why?
|
| Pregnancy Complications | 5 | 2023 | 542 | 0.780 |
Why?
|
| Pulmonary Valve | 2 | 2021 | 89 | 0.730 |
Why?
|
| Risk Factors | 29 | 2025 | 10397 | 0.710 |
Why?
|
| Ventricular Dysfunction, Left | 5 | 2024 | 352 | 0.710 |
Why?
|
| Adult | 46 | 2025 | 30254 | 0.710 |
Why?
|
| Patient Discharge | 1 | 2025 | 467 | 0.710 |
Why?
|
| DiGeorge Syndrome | 1 | 2021 | 79 | 0.700 |
Why?
|
| Connective Tissue Diseases | 4 | 2016 | 29 | 0.690 |
Why?
|
| Aortic Coarctation | 1 | 2021 | 96 | 0.680 |
Why?
|
| Urinary Bladder Diseases | 1 | 2020 | 33 | 0.670 |
Why?
|
| Down Syndrome | 3 | 2020 | 201 | 0.670 |
Why?
|
| Hospitalization | 5 | 2024 | 1838 | 0.670 |
Why?
|
| Hospitals | 2 | 2021 | 417 | 0.660 |
Why?
|
| Abnormalities, Multiple | 4 | 2019 | 964 | 0.650 |
Why?
|
| Pregnancy Complications, Cardiovascular | 2 | 2018 | 107 | 0.650 |
Why?
|
| Mutation | 13 | 2024 | 5926 | 0.650 |
Why?
|
| Pulmonary Veins | 2 | 2021 | 172 | 0.640 |
Why?
|
| Texas | 14 | 2024 | 3532 | 0.630 |
Why?
|
| Ebstein Anomaly | 4 | 2021 | 29 | 0.620 |
Why?
|
| Life Support Care | 1 | 2019 | 48 | 0.610 |
Why?
|
| Mitral Valve Annuloplasty | 1 | 2019 | 14 | 0.610 |
Why?
|
| United States | 21 | 2025 | 11204 | 0.600 |
Why?
|
| Receptors, Transforming Growth Factor beta | 2 | 2016 | 104 | 0.580 |
Why?
|
| Magnetic Resonance Imaging, Cine | 5 | 2024 | 170 | 0.570 |
Why?
|
| Vascular Resistance | 2 | 2018 | 186 | 0.570 |
Why?
|
| Disease Progression | 1 | 2024 | 2099 | 0.560 |
Why?
|
| Attitude to Health | 1 | 2019 | 242 | 0.560 |
Why?
|
| Heart Atria | 4 | 2020 | 327 | 0.560 |
Why?
|
| Influenza, Human | 1 | 2024 | 674 | 0.560 |
Why?
|
| Meningomyelocele | 1 | 2021 | 249 | 0.550 |
Why?
|
| Consensus | 2 | 2019 | 544 | 0.540 |
Why?
|
| Aortic Rupture | 2 | 2016 | 103 | 0.530 |
Why?
|
| Family | 1 | 2019 | 574 | 0.500 |
Why?
|
| Aortic Aneurysm | 3 | 2017 | 186 | 0.490 |
Why?
|
| Young Adult | 26 | 2025 | 9616 | 0.480 |
Why?
|
| Vascular Surgical Procedures | 2 | 2019 | 488 | 0.470 |
Why?
|
| Cerebrovascular Circulation | 1 | 2018 | 449 | 0.460 |
Why?
|
| Patient Care Team | 1 | 2019 | 548 | 0.460 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2019 | 399 | 0.460 |
Why?
|
| Time Factors | 12 | 2025 | 6016 | 0.460 |
Why?
|
| Fetus | 5 | 2022 | 578 | 0.460 |
Why?
|
| Oxygen | 1 | 2018 | 540 | 0.450 |
Why?
|
| Pulmonary Valve Stenosis | 3 | 2024 | 40 | 0.440 |
Why?
|
| Treatment Outcome | 22 | 2025 | 12328 | 0.440 |
Why?
|
| Cesarean Section | 1 | 2018 | 424 | 0.440 |
Why?
|
| Tricuspid Valve | 3 | 2020 | 62 | 0.440 |
Why?
|
| Calcium Channels | 6 | 2001 | 147 | 0.440 |
Why?
|
| Phenotype | 13 | 2025 | 4304 | 0.440 |
Why?
|
| Mitral Valve Prolapse | 2 | 2024 | 34 | 0.440 |
Why?
|
| Databases, Factual | 6 | 2022 | 1176 | 0.430 |
Why?
|
| Trypanosoma cruzi | 7 | 1998 | 251 | 0.430 |
Why?
|
| Fetal Therapies | 3 | 2020 | 83 | 0.420 |
Why?
|
| Collagen Type III | 3 | 2025 | 24 | 0.420 |
Why?
|
| Cardiomyopathies | 4 | 2024 | 493 | 0.400 |
Why?
|
| Cohort Studies | 11 | 2024 | 4920 | 0.400 |
Why?
|
| Predictive Value of Tests | 7 | 2024 | 2190 | 0.400 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 6 | 2001 | 319 | 0.390 |
Why?
|
| Smad3 Protein | 2 | 2024 | 52 | 0.380 |
Why?
|
| Vertebral Artery | 2 | 2014 | 18 | 0.380 |
Why?
|
| Length of Stay | 5 | 2024 | 1324 | 0.380 |
Why?
|
| Thoracic Surgery | 1 | 2013 | 149 | 0.360 |
Why?
|
| Tricuspid Valve Insufficiency | 3 | 2021 | 64 | 0.350 |
Why?
|
| Risk Assessment | 8 | 2025 | 3461 | 0.350 |
Why?
|
| DNA | 2 | 2020 | 1422 | 0.350 |
Why?
|
| Pedigree | 2 | 2024 | 1655 | 0.340 |
Why?
|
| Wolff-Parkinson-White Syndrome | 2 | 2022 | 73 | 0.330 |
Why?
|
| Actins | 2 | 2026 | 311 | 0.330 |
Why?
|
| Echocardiography, Doppler, Color | 3 | 2021 | 114 | 0.320 |
Why?
|
| Umbilical Arteries | 2 | 2022 | 98 | 0.320 |
Why?
|
| Dilatation, Pathologic | 3 | 2021 | 79 | 0.320 |
Why?
|
| Calcium | 7 | 2001 | 1031 | 0.310 |
Why?
|
| Balloon Valvuloplasty | 2 | 2020 | 23 | 0.310 |
Why?
|
| Age Factors | 8 | 2024 | 2772 | 0.300 |
Why?
|
| Pregnancy Outcome | 6 | 2021 | 625 | 0.300 |
Why?
|
| Infant, Newborn, Diseases | 2 | 2022 | 175 | 0.300 |
Why?
|
| Inpatients | 1 | 2013 | 539 | 0.290 |
Why?
|
| Magnetic Resonance Angiography | 4 | 2019 | 159 | 0.290 |
Why?
|
| Live Birth | 4 | 2021 | 65 | 0.290 |
Why?
|
| Cardiology | 3 | 2020 | 475 | 0.280 |
Why?
|
| Ventricular Dysfunction, Right | 2 | 2021 | 76 | 0.270 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2025 | 3256 | 0.270 |
Why?
|
| Attitude of Health Personnel | 2 | 2025 | 693 | 0.270 |
Why?
|
| Tachycardia, Supraventricular | 2 | 2022 | 108 | 0.270 |
Why?
|
| Genetic Testing | 3 | 2024 | 1060 | 0.260 |
Why?
|
| Genotype | 6 | 2024 | 2600 | 0.260 |
Why?
|
| Fetal Diseases | 4 | 2024 | 455 | 0.260 |
Why?
|
| Postoperative Complications | 7 | 2022 | 2968 | 0.250 |
Why?
|
| Fibrillin-1 | 5 | 2025 | 54 | 0.250 |
Why?
|
| Heat Shock Transcription Factors | 1 | 2026 | 21 | 0.240 |
Why?
|
| Filamins | 2 | 2017 | 27 | 0.240 |
Why?
|
| Severity of Illness Index | 5 | 2025 | 2936 | 0.240 |
Why?
|
| Heart Septal Defects, Ventricular | 2 | 2020 | 137 | 0.240 |
Why?
|
| Verapamil | 4 | 1996 | 46 | 0.230 |
Why?
|
| Chagas Cardiomyopathy | 7 | 1994 | 51 | 0.230 |
Why?
|
| Ultrasonography, Doppler | 3 | 2021 | 181 | 0.230 |
Why?
|
| Transforming Growth Factor beta3 | 1 | 2025 | 6 | 0.230 |
Why?
|
| Cause of Death | 2 | 2018 | 473 | 0.230 |
Why?
|
| Pilot Projects | 5 | 2023 | 1386 | 0.230 |
Why?
|
| Vascular Stiffness | 2 | 2016 | 77 | 0.220 |
Why?
|
| Jaundice, Neonatal | 1 | 2004 | 10 | 0.220 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2026 | 176 | 0.220 |
Why?
|
| Losartan | 2 | 2020 | 34 | 0.220 |
Why?
|
| Choice Behavior | 1 | 2025 | 132 | 0.220 |
Why?
|
| Parathyroid Hormone | 2 | 2008 | 77 | 0.220 |
Why?
|
| Incidence | 7 | 2017 | 3213 | 0.220 |
Why?
|
| Coronary Vessels | 3 | 2019 | 523 | 0.220 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2018 | 1025 | 0.210 |
Why?
|
| Smad4 Protein | 1 | 2024 | 56 | 0.210 |
Why?
|
| Prospective Studies | 8 | 2022 | 6093 | 0.210 |
Why?
|
| Health Information Systems | 1 | 2024 | 31 | 0.210 |
Why?
|
| Elastin | 1 | 2024 | 24 | 0.210 |
Why?
|
| Fetal Death | 2 | 2021 | 119 | 0.210 |
Why?
|
| Counseling | 1 | 2025 | 232 | 0.210 |
Why?
|
| Prevalence | 5 | 2024 | 2579 | 0.210 |
Why?
|
| Pulmonary Atresia | 2 | 2024 | 48 | 0.200 |
Why?
|
| Middle Aged | 16 | 2026 | 27331 | 0.200 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2014 | 75 | 0.200 |
Why?
|
| Multicenter Studies as Topic | 1 | 2024 | 280 | 0.200 |
Why?
|
| RNA Splicing | 1 | 2024 | 231 | 0.200 |
Why?
|
| Propensity Score | 1 | 2024 | 238 | 0.200 |
Why?
|
| Cholesterol | 1 | 2026 | 538 | 0.200 |
Why?
|
| Immunization | 1 | 2004 | 301 | 0.200 |
Why?
|
| Palliative Care | 4 | 2020 | 438 | 0.190 |
Why?
|
| Fibrillins | 4 | 2022 | 23 | 0.190 |
Why?
|
| Disease Management | 2 | 2024 | 533 | 0.190 |
Why?
|
| DNA Copy Number Variations | 2 | 2018 | 1003 | 0.190 |
Why?
|
| American Heart Association | 1 | 2024 | 305 | 0.190 |
Why?
|
| Respiration, Artificial | 2 | 2024 | 486 | 0.190 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2014 | 208 | 0.190 |
Why?
|
| Ectopia Lentis | 1 | 2022 | 11 | 0.190 |
Why?
|
| Maternal-Fetal Exchange | 2 | 2020 | 80 | 0.180 |
Why?
|
| Adenylyl Cyclases | 6 | 1999 | 60 | 0.180 |
Why?
|
| Sex Factors | 4 | 2020 | 1294 | 0.180 |
Why?
|
| Obesity | 1 | 2013 | 2330 | 0.180 |
Why?
|
| Regression Analysis | 3 | 2018 | 757 | 0.180 |
Why?
|
| Chromosome Deletion | 2 | 2021 | 642 | 0.180 |
Why?
|
| Ataxia | 1 | 2022 | 160 | 0.170 |
Why?
|
| Multivariate Analysis | 3 | 2019 | 1350 | 0.170 |
Why?
|
| Medical Illustration | 1 | 2021 | 18 | 0.170 |
Why?
|
| Follow-Up Studies | 10 | 2020 | 5050 | 0.170 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2024 | 3680 | 0.170 |
Why?
|
| Ecchymosis | 1 | 2020 | 12 | 0.170 |
Why?
|
| Rupture, Spontaneous | 1 | 2020 | 46 | 0.170 |
Why?
|
| Peritoneal Cavity | 1 | 2020 | 20 | 0.170 |
Why?
|
| Hospital Charges | 1 | 2021 | 64 | 0.170 |
Why?
|
| Vena Cava, Inferior | 1 | 2021 | 99 | 0.170 |
Why?
|
| Receptors, Adrenergic, beta-1 | 1 | 2020 | 13 | 0.170 |
Why?
|
| Hernia, Inguinal | 1 | 2020 | 41 | 0.170 |
Why?
|
| Chagas Disease | 5 | 1996 | 309 | 0.170 |
Why?
|
| Pulmonary Valve Insufficiency | 1 | 2020 | 41 | 0.170 |
Why?
|
| Cytochrome P-450 CYP2C9 | 1 | 2020 | 5 | 0.170 |
Why?
|
| Mutation, Missense | 2 | 2026 | 888 | 0.170 |
Why?
|
| Atenolol | 1 | 2020 | 43 | 0.160 |
Why?
|
| Herniorrhaphy | 1 | 2020 | 72 | 0.160 |
Why?
|
| Intersectoral Collaboration | 1 | 2020 | 18 | 0.160 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2023 | 223 | 0.160 |
Why?
|
| Health Services Misuse | 1 | 2000 | 24 | 0.160 |
Why?
|
| Ductus Arteriosus | 1 | 2020 | 61 | 0.160 |
Why?
|
| Neurovascular Coupling | 1 | 2019 | 10 | 0.160 |
Why?
|
| Stakeholder Participation | 1 | 2020 | 31 | 0.160 |
Why?
|
| Bioethical Issues | 1 | 2019 | 22 | 0.160 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2000 | 73 | 0.160 |
Why?
|
| GTP-Binding Proteins | 3 | 1996 | 159 | 0.160 |
Why?
|
| Treatment Refusal | 1 | 2020 | 76 | 0.160 |
Why?
|
| Myocarditis | 1 | 2021 | 124 | 0.160 |
Why?
|
| Abdominal Injuries | 1 | 2020 | 113 | 0.160 |
Why?
|
| Hospitals, Urban | 1 | 2000 | 98 | 0.160 |
Why?
|
| Prognosis | 5 | 2021 | 4709 | 0.150 |
Why?
|
| Isolated Noncompaction of the Ventricular Myocardium | 1 | 2019 | 42 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2018 | 2026 | 0.150 |
Why?
|
| Accidental Falls | 1 | 2020 | 114 | 0.150 |
Why?
|
| Coronary Occlusion | 1 | 2019 | 31 | 0.150 |
Why?
|
| Thulium | 1 | 2019 | 10 | 0.150 |
Why?
|
| Defibrillators, Implantable | 1 | 2022 | 210 | 0.150 |
Why?
|
| Proton-Translocating ATPases | 1 | 1999 | 18 | 0.150 |
Why?
|
| Longevity | 1 | 2020 | 151 | 0.150 |
Why?
|
| Case-Control Studies | 3 | 2018 | 3303 | 0.150 |
Why?
|
| Vacuolar Proton-Translocating ATPases | 1 | 1999 | 20 | 0.150 |
Why?
|
| Lymphatic Vessels | 1 | 2019 | 33 | 0.150 |
Why?
|
| Clinical Decision-Making | 2 | 2018 | 299 | 0.150 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2020 | 121 | 0.150 |
Why?
|
| Diastole | 2 | 2020 | 171 | 0.150 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-3 | 1 | 2018 | 4 | 0.150 |
Why?
|
| Physicians | 1 | 2025 | 618 | 0.150 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2018 | 38 | 0.150 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 293 | 0.150 |
Why?
|
| Proportional Hazards Models | 3 | 2016 | 1350 | 0.150 |
Why?
|
| Lymphatic Abnormalities | 1 | 2019 | 36 | 0.150 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2024 | 474 | 0.150 |
Why?
|
| Clinical Competence | 3 | 2017 | 1018 | 0.140 |
Why?
|
| Coronary Circulation | 1 | 2019 | 188 | 0.140 |
Why?
|
| Genetic Variation | 1 | 2025 | 1520 | 0.140 |
Why?
|
| Stents | 3 | 2019 | 741 | 0.140 |
Why?
|
| Perinatal Care | 1 | 2019 | 67 | 0.140 |
Why?
|
| Pulmonary Artery | 2 | 2025 | 445 | 0.140 |
Why?
|
| Vasodilator Agents | 3 | 2016 | 190 | 0.140 |
Why?
|
| Abdominal Pain | 1 | 2020 | 306 | 0.140 |
Why?
|
| Truncus Arteriosus, Persistent | 1 | 2018 | 19 | 0.140 |
Why?
|
| Uterine Artery | 1 | 2018 | 25 | 0.140 |
Why?
|
| Pulsatile Flow | 1 | 2018 | 120 | 0.140 |
Why?
|
| Atherosclerosis | 1 | 2026 | 929 | 0.140 |
Why?
|
| Heart-Assist Devices | 2 | 2019 | 1035 | 0.140 |
Why?
|
| Mydriasis | 1 | 2018 | 8 | 0.140 |
Why?
|
| Tracheostomy | 1 | 2020 | 214 | 0.140 |
Why?
|
| Neck | 1 | 2019 | 141 | 0.140 |
Why?
|
| Electrocardiography | 3 | 2019 | 918 | 0.140 |
Why?
|
| Eye Diseases, Hereditary | 1 | 2018 | 29 | 0.140 |
Why?
|
| Transcription Factors | 2 | 2024 | 2341 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 1 | 2024 | 1227 | 0.140 |
Why?
|
| Seizures | 1 | 2022 | 847 | 0.140 |
Why?
|
| Fluorescent Dyes | 1 | 1999 | 245 | 0.140 |
Why?
|
| Esophageal Atresia | 1 | 2018 | 51 | 0.140 |
Why?
|
| Tracheoesophageal Fistula | 1 | 2018 | 48 | 0.130 |
Why?
|
| Signal Transduction | 5 | 2016 | 4468 | 0.130 |
Why?
|
| Ventricular Function, Right | 2 | 2021 | 113 | 0.130 |
Why?
|
| Imidazoles | 1 | 1999 | 217 | 0.130 |
Why?
|
| Reproducibility of Results | 4 | 2023 | 2875 | 0.130 |
Why?
|
| Pyridines | 1 | 1999 | 248 | 0.130 |
Why?
|
| Walking | 1 | 2019 | 229 | 0.130 |
Why?
|
| Age of Onset | 3 | 2026 | 609 | 0.130 |
Why?
|
| Patient Participation | 1 | 2020 | 230 | 0.130 |
Why?
|
| Pectus Carinatum | 1 | 2017 | 5 | 0.130 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2019 | 277 | 0.130 |
Why?
|
| Pacemaker, Artificial | 2 | 2017 | 187 | 0.130 |
Why?
|
| Ultrasonography, Interventional | 1 | 2019 | 199 | 0.130 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2020 | 249 | 0.130 |
Why?
|
| Animals | 25 | 2024 | 33120 | 0.130 |
Why?
|
| Arterio-Arterial Fistula | 1 | 2016 | 10 | 0.130 |
Why?
|
| Heart Conduction System | 1 | 2017 | 152 | 0.130 |
Why?
|
| Health Expenditures | 1 | 2018 | 132 | 0.130 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2017 | 51 | 0.130 |
Why?
|
| Pericardium | 1 | 2017 | 102 | 0.120 |
Why?
|
| Calcium Channel Blockers | 1 | 1996 | 108 | 0.120 |
Why?
|
| Lung | 2 | 2021 | 1519 | 0.120 |
Why?
|
| Myocardial Contraction | 2 | 2017 | 238 | 0.120 |
Why?
|
| Antifungal Agents | 2 | 2000 | 290 | 0.120 |
Why?
|
| Soluble Guanylyl Cyclase | 1 | 2016 | 7 | 0.120 |
Why?
|
| Heart Neoplasms | 1 | 2017 | 104 | 0.120 |
Why?
|
| Teratoma | 1 | 2017 | 120 | 0.120 |
Why?
|
| Hemodynamics | 2 | 2017 | 802 | 0.120 |
Why?
|
| Hypertension | 2 | 2016 | 1289 | 0.120 |
Why?
|
| Laboratory Proficiency Testing | 1 | 2016 | 10 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2016 | 32 | 0.120 |
Why?
|
| Pediatrics | 3 | 2017 | 1202 | 0.120 |
Why?
|
| Ductus Arteriosus, Patent | 1 | 2018 | 142 | 0.120 |
Why?
|
| Enzyme Inhibitors | 1 | 1999 | 565 | 0.120 |
Why?
|
| Equipment and Supplies, Hospital | 1 | 2015 | 10 | 0.120 |
Why?
|
| Gene Expression Regulation | 3 | 2020 | 2313 | 0.120 |
Why?
|
| Critical Illness | 1 | 2020 | 603 | 0.120 |
Why?
|
| Alprostadil | 1 | 2015 | 22 | 0.120 |
Why?
|
| Moyamoya Disease | 1 | 2016 | 40 | 0.120 |
Why?
|
| Program Evaluation | 1 | 2017 | 436 | 0.120 |
Why?
|
| Esophageal Achalasia | 1 | 2016 | 44 | 0.120 |
Why?
|
| Myocardium | 5 | 2014 | 843 | 0.120 |
Why?
|
| Aortography | 1 | 2016 | 148 | 0.120 |
Why?
|
| Atrioventricular Block | 1 | 2016 | 44 | 0.120 |
Why?
|
| Inositol 1,4,5-Trisphosphate Receptors | 6 | 2001 | 33 | 0.120 |
Why?
|
| Hypertension, Pulmonary | 2 | 2017 | 443 | 0.120 |
Why?
|
| Heart | 2 | 2017 | 650 | 0.120 |
Why?
|
| International Cooperation | 1 | 2015 | 157 | 0.110 |
Why?
|
| Acute Kidney Injury | 1 | 2022 | 657 | 0.110 |
Why?
|
| Respiratory Insufficiency | 1 | 2017 | 237 | 0.110 |
Why?
|
| Pneumocystis | 1 | 1994 | 9 | 0.110 |
Why?
|
| Genetic Association Studies | 2 | 2017 | 807 | 0.110 |
Why?
|
| Echocardiography, Doppler | 1 | 2015 | 164 | 0.110 |
Why?
|
| Heterozygote | 1 | 2016 | 690 | 0.110 |
Why?
|
| Hyperoxia | 1 | 2016 | 134 | 0.110 |
Why?
|
| Fracture Fixation | 1 | 2014 | 28 | 0.110 |
Why?
|
| Prostheses and Implants | 1 | 2016 | 144 | 0.110 |
Why?
|
| Respiration | 1 | 2015 | 119 | 0.110 |
Why?
|
| Statistics as Topic | 1 | 2015 | 238 | 0.110 |
Why?
|
| Adipokines | 2 | 2025 | 111 | 0.110 |
Why?
|
| Biomedical Research | 1 | 2020 | 527 | 0.110 |
Why?
|
| Aneurysm | 1 | 2014 | 69 | 0.110 |
Why?
|
| Endothelium, Vascular | 3 | 1996 | 460 | 0.110 |
Why?
|
| Mass Screening | 1 | 2019 | 805 | 0.100 |
Why?
|
| Internship and Residency | 2 | 2017 | 1194 | 0.100 |
Why?
|
| Aged | 7 | 2025 | 20005 | 0.100 |
Why?
|
| DNA Mutational Analysis | 1 | 2015 | 780 | 0.100 |
Why?
|
| Primary Health Care | 1 | 2000 | 771 | 0.100 |
Why?
|
| Tibial Fractures | 1 | 2014 | 64 | 0.100 |
Why?
|
| Comorbidity | 2 | 2016 | 1538 | 0.100 |
Why?
|
| Heart Arrest | 1 | 2017 | 359 | 0.100 |
Why?
|
| Lung Diseases | 1 | 2017 | 392 | 0.100 |
Why?
|
| Cardiac Volume | 1 | 2013 | 18 | 0.100 |
Why?
|
| Protozoan Proteins | 1 | 1994 | 133 | 0.100 |
Why?
|
| Tachycardia, Ventricular | 1 | 2016 | 254 | 0.100 |
Why?
|
| Nitric Oxide | 1 | 2016 | 463 | 0.100 |
Why?
|
| Lung Transplantation | 1 | 2017 | 344 | 0.100 |
Why?
|
| Education, Medical, Continuing | 1 | 2013 | 129 | 0.090 |
Why?
|
| Emergency Service, Hospital | 1 | 2000 | 1025 | 0.090 |
Why?
|
| Survival Rate | 4 | 2019 | 2060 | 0.090 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 2 | 2020 | 56 | 0.090 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 542 | 0.090 |
Why?
|
| Time-to-Treatment | 1 | 2013 | 196 | 0.090 |
Why?
|
| Hospital Costs | 1 | 2013 | 172 | 0.090 |
Why?
|
| Cyclic AMP | 1 | 1992 | 223 | 0.090 |
Why?
|
| Protein Isoforms | 2 | 2024 | 402 | 0.090 |
Why?
|
| Microfilament Proteins | 2 | 2021 | 264 | 0.090 |
Why?
|
| Perinatal Mortality | 2 | 2020 | 44 | 0.080 |
Why?
|
| Peptides | 1 | 1994 | 828 | 0.080 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 866 | 0.080 |
Why?
|
| Odds Ratio | 1 | 2013 | 1189 | 0.080 |
Why?
|
| Exome | 2 | 2025 | 1064 | 0.080 |
Why?
|
| Cardiovascular Diseases | 2 | 2019 | 2024 | 0.080 |
Why?
|
| Propranolol | 2 | 2022 | 111 | 0.080 |
Why?
|
| Organ Size | 2 | 2016 | 435 | 0.080 |
Why?
|
| Wounds and Injuries | 1 | 2013 | 377 | 0.080 |
Why?
|
| Observer Variation | 2 | 2023 | 304 | 0.080 |
Why?
|
| Heart Failure | 1 | 2022 | 2175 | 0.070 |
Why?
|
| Genome-Wide Association Study | 1 | 2016 | 1730 | 0.070 |
Why?
|
| Congenital Abnormalities | 2 | 2024 | 300 | 0.070 |
Why?
|
| Cross-Sectional Studies | 3 | 2024 | 3649 | 0.070 |
Why?
|
| Quality of Life | 2 | 2020 | 2023 | 0.070 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2008 | 31 | 0.070 |
Why?
|
| Progestins | 1 | 2008 | 42 | 0.070 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2008 | 48 | 0.070 |
Why?
|
| Calmodulin | 2 | 2000 | 206 | 0.070 |
Why?
|
| Cells, Cultured | 5 | 1999 | 2902 | 0.070 |
Why?
|
| Research Design | 2 | 2024 | 687 | 0.070 |
Why?
|
| Surveys and Questionnaires | 3 | 2025 | 3905 | 0.070 |
Why?
|
| Mitosporic Fungi | 2 | 2000 | 8 | 0.070 |
Why?
|
| Europe | 2 | 2020 | 355 | 0.070 |
Why?
|
| Brain | 2 | 2018 | 3032 | 0.070 |
Why?
|
| Longitudinal Studies | 2 | 2025 | 1421 | 0.070 |
Why?
|
| Body Mass Index | 1 | 2013 | 1649 | 0.060 |
Why?
|
| Drainage | 2 | 2018 | 249 | 0.060 |
Why?
|
| Bone Density | 1 | 2008 | 351 | 0.060 |
Why?
|
| Estrogens | 1 | 2008 | 424 | 0.060 |
Why?
|
| Health Services Research | 2 | 2013 | 175 | 0.060 |
Why?
|
| Glucose Transport Proteins, Facilitative | 1 | 2025 | 22 | 0.060 |
Why?
|
| Infant, Premature, Diseases | 2 | 2020 | 236 | 0.060 |
Why?
|
| Cardiologists | 1 | 2025 | 25 | 0.060 |
Why?
|
| Kinetics | 4 | 2001 | 1090 | 0.060 |
Why?
|
| Fibrillin-2 | 1 | 2024 | 3 | 0.060 |
Why?
|
| Cardiac Myosins | 1 | 2024 | 11 | 0.060 |
Why?
|
| Receptors, Adrenergic, beta | 3 | 1994 | 45 | 0.060 |
Why?
|
| Salmonella Infections, Animal | 1 | 2004 | 6 | 0.060 |
Why?
|
| Measles Vaccine | 1 | 2004 | 12 | 0.060 |
Why?
|
| Chickenpox Vaccine | 1 | 2004 | 14 | 0.060 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2024 | 62 | 0.050 |
Why?
|
| Viral Hepatitis Vaccines | 1 | 2004 | 19 | 0.050 |
Why?
|
| Animals, Domestic | 1 | 2004 | 33 | 0.050 |
Why?
|
| Bites and Stings | 1 | 2004 | 27 | 0.050 |
Why?
|
| Hyperbilirubinemia | 1 | 2004 | 41 | 0.050 |
Why?
|
| Clubfoot | 1 | 2024 | 21 | 0.050 |
Why?
|
| Hospitals, General | 1 | 2024 | 24 | 0.050 |
Why?
|
| Myosin Heavy Chains | 1 | 2024 | 73 | 0.050 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2014 | 23 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 2 | 2013 | 529 | 0.050 |
Why?
|
| Curriculum | 3 | 2017 | 767 | 0.050 |
Why?
|
| Massachusetts | 1 | 2024 | 116 | 0.050 |
Why?
|
| Cryptorchidism | 1 | 2024 | 38 | 0.050 |
Why?
|
| Rotavirus Vaccines | 1 | 2004 | 60 | 0.050 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2014 | 47 | 0.050 |
Why?
|
| Facies | 1 | 2024 | 156 | 0.050 |
Why?
|
| Whooping Cough | 1 | 2004 | 62 | 0.050 |
Why?
|
| Bilirubin | 1 | 2004 | 124 | 0.050 |
Why?
|
| Genomics | 2 | 2025 | 1571 | 0.050 |
Why?
|
| Adenosine | 2 | 2001 | 126 | 0.050 |
Why?
|
| Rabbits | 1 | 2004 | 612 | 0.050 |
Why?
|
| Rats | 6 | 2000 | 3387 | 0.050 |
Why?
|
| Dogs | 1 | 2004 | 603 | 0.050 |
Why?
|
| Hand Deformities, Congenital | 1 | 2024 | 95 | 0.050 |
Why?
|
| Patient Readmission | 2 | 2020 | 388 | 0.050 |
Why?
|
| Mice | 8 | 2014 | 17585 | 0.050 |
Why?
|
| Growth Disorders | 1 | 2024 | 184 | 0.050 |
Why?
|
| Extracellular Matrix | 1 | 2014 | 223 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 1994 | 2495 | 0.050 |
Why?
|
| MAP Kinase Signaling System | 1 | 2014 | 301 | 0.050 |
Why?
|
| Fellowships and Scholarships | 2 | 2017 | 314 | 0.050 |
Why?
|
| Cytosol | 2 | 1999 | 139 | 0.050 |
Why?
|
| Biological Variation, Population | 1 | 2022 | 26 | 0.050 |
Why?
|
| Transforming Growth Factor beta | 1 | 2024 | 447 | 0.050 |
Why?
|
| Vesicular Transport Proteins | 1 | 2022 | 137 | 0.050 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2001 | 58 | 0.040 |
Why?
|
| Platelet Activation | 1 | 2001 | 66 | 0.040 |
Why?
|
| Blood Flow Velocity | 2 | 2020 | 430 | 0.040 |
Why?
|
| Tyrosine | 1 | 2001 | 146 | 0.040 |
Why?
|
| Homeodomain Proteins | 1 | 2024 | 538 | 0.040 |
Why?
|
| Chromosome Mapping | 3 | 2016 | 1065 | 0.040 |
Why?
|
| Geography | 1 | 2021 | 120 | 0.040 |
Why?
|
| Mitochondrial Proteins | 1 | 2022 | 272 | 0.040 |
Why?
|
| Constriction | 1 | 2020 | 43 | 0.040 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2022 | 225 | 0.040 |
Why?
|
| Pneumonia | 1 | 2004 | 333 | 0.040 |
Why?
|
| Indomethacin | 1 | 2020 | 81 | 0.040 |
Why?
|
| Ibuprofen | 1 | 2020 | 41 | 0.040 |
Why?
|
| Adrenergic beta-1 Receptor Antagonists | 1 | 2020 | 14 | 0.040 |
Why?
|
| Cell Line | 3 | 2001 | 2565 | 0.040 |
Why?
|
| Canada | 1 | 2021 | 315 | 0.040 |
Why?
|
| Life Tables | 1 | 2000 | 24 | 0.040 |
Why?
|
| Creatinine | 1 | 2022 | 378 | 0.040 |
Why?
|
| Saponins | 1 | 2000 | 21 | 0.040 |
Why?
|
| New York City | 1 | 2000 | 63 | 0.040 |
Why?
|
| Amino Acid Sequence | 2 | 1994 | 2544 | 0.040 |
Why?
|
| Holistic Health | 1 | 2020 | 12 | 0.040 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2020 | 49 | 0.040 |
Why?
|
| Triterpenes | 1 | 2000 | 21 | 0.040 |
Why?
|
| Prenatal Care | 1 | 2022 | 357 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2000 | 678 | 0.040 |
Why?
|
| Subcellular Fractions | 1 | 1999 | 87 | 0.040 |
Why?
|
| Social Class | 1 | 2021 | 198 | 0.040 |
Why?
|
| Biopsy | 1 | 2023 | 1234 | 0.040 |
Why?
|
| Prazosin | 2 | 1996 | 16 | 0.040 |
Why?
|
| Influenza Vaccines | 1 | 2004 | 481 | 0.040 |
Why?
|
| Radiography | 2 | 2014 | 749 | 0.040 |
Why?
|
| North America | 1 | 2020 | 250 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 1999 | 58 | 0.040 |
Why?
|
| Graft Rejection | 1 | 2023 | 553 | 0.040 |
Why?
|
| Adenosine Diphosphate | 2 | 2001 | 52 | 0.040 |
Why?
|
| Molecular Sequence Data | 2 | 1994 | 3599 | 0.040 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2022 | 270 | 0.040 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 1999 | 14 | 0.040 |
Why?
|
| Type C Phospholipases | 1 | 1999 | 16 | 0.040 |
Why?
|
| Scintillation Counting | 1 | 1999 | 6 | 0.040 |
Why?
|
| Baculoviridae | 1 | 1999 | 41 | 0.040 |
Why?
|
| Infant Care | 1 | 2019 | 46 | 0.040 |
Why?
|
| Myocytes, Cardiac | 1 | 2014 | 609 | 0.040 |
Why?
|
| Anthropometry | 1 | 1999 | 191 | 0.040 |
Why?
|
| Insecta | 1 | 1999 | 58 | 0.040 |
Why?
|
| Bone Resorption | 1 | 1999 | 50 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2020 | 238 | 0.040 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2021 | 247 | 0.040 |
Why?
|
| Osteoclasts | 1 | 1999 | 64 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2014 | 2311 | 0.040 |
Why?
|
| Parturition | 1 | 2019 | 66 | 0.040 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2018 | 56 | 0.040 |
Why?
|
| Mitral Valve Stenosis | 1 | 2018 | 34 | 0.040 |
Why?
|
| Protein Binding | 2 | 2000 | 1661 | 0.040 |
Why?
|
| Valinomycin | 1 | 1998 | 1 | 0.040 |
Why?
|
| Nigericin | 1 | 1998 | 3 | 0.040 |
Why?
|
| Ionophores | 1 | 1998 | 9 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2000 | 313 | 0.040 |
Why?
|
| Thapsigargin | 1 | 1998 | 21 | 0.040 |
Why?
|
| Monensin | 1 | 1998 | 8 | 0.040 |
Why?
|
| Biological Transport, Active | 1 | 1998 | 73 | 0.030 |
Why?
|
| Transplant Recipients | 1 | 2020 | 230 | 0.030 |
Why?
|
| Terpenes | 1 | 1998 | 30 | 0.030 |
Why?
|
| Chromosomes, Human, X | 1 | 2018 | 151 | 0.030 |
Why?
|
| Microsomes | 1 | 1997 | 37 | 0.030 |
Why?
|
| Cerebellum | 2 | 2000 | 414 | 0.030 |
Why?
|
| MEDLINE | 1 | 2017 | 18 | 0.030 |
Why?
|
| Norwood Procedures | 1 | 2019 | 100 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2017 | 2750 | 0.030 |
Why?
|
| Birth Weight | 2 | 2015 | 340 | 0.030 |
Why?
|
| Bone and Bones | 1 | 2019 | 295 | 0.030 |
Why?
|
| Muscle, Smooth | 1 | 2018 | 129 | 0.030 |
Why?
|
| Insurance, Health | 1 | 2018 | 133 | 0.030 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2017 | 42 | 0.030 |
Why?
|
| Inheritance Patterns | 1 | 2017 | 128 | 0.030 |
Why?
|
| Coronary Angiography | 1 | 2019 | 447 | 0.030 |
Why?
|
| Drosophila | 1 | 2001 | 779 | 0.030 |
Why?
|
| Medical Records | 1 | 2018 | 178 | 0.030 |
Why?
|
| Genetic Heterogeneity | 1 | 2017 | 129 | 0.030 |
Why?
|
| Intellectual Disability | 1 | 2024 | 1045 | 0.030 |
Why?
|
| Microcirculation | 3 | 1996 | 108 | 0.030 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2020 | 335 | 0.030 |
Why?
|
| Diseases in Twins | 1 | 2017 | 91 | 0.030 |
Why?
|
| Hydrops Fetalis | 1 | 2017 | 85 | 0.030 |
Why?
|
| Diltiazem | 1 | 1996 | 14 | 0.030 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 1996 | 39 | 0.030 |
Why?
|
| Umbilical Veins | 1 | 1996 | 64 | 0.030 |
Why?
|
| Stillbirth | 1 | 2017 | 96 | 0.030 |
Why?
|
| Acute Disease | 2 | 1996 | 1046 | 0.030 |
Why?
|
| Mental Health | 1 | 2020 | 364 | 0.030 |
Why?
|
| Australia | 1 | 2016 | 154 | 0.030 |
Why?
|
| Japan | 1 | 2016 | 171 | 0.030 |
Why?
|
| Sf9 Cells | 1 | 2016 | 10 | 0.030 |
Why?
|
| Allografts | 1 | 2017 | 184 | 0.030 |
Why?
|
| Biomechanical Phenomena | 1 | 2017 | 252 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2018 | 283 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2000 | 556 | 0.030 |
Why?
|
| Nonlinear Dynamics | 1 | 2016 | 54 | 0.030 |
Why?
|
| Inositol 1,4,5-Trisphosphate | 3 | 2001 | 10 | 0.030 |
Why?
|
| Heart Septal Defects | 1 | 2016 | 36 | 0.030 |
Why?
|
| Aorta, Abdominal | 1 | 2016 | 93 | 0.030 |
Why?
|
| Logistic Models | 1 | 2020 | 1745 | 0.030 |
Why?
|
| Birthing Centers | 1 | 2015 | 9 | 0.030 |
Why?
|
| Alleles | 1 | 2020 | 1611 | 0.030 |
Why?
|
| Causality | 1 | 2016 | 89 | 0.030 |
Why?
|
| Incidental Findings | 1 | 2016 | 119 | 0.030 |
Why?
|
| Abortion, Eugenic | 1 | 2015 | 9 | 0.030 |
Why?
|
| Computed Tomography Angiography | 1 | 2017 | 203 | 0.030 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2017 | 249 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 1096 | 0.030 |
Why?
|
| Arginine | 1 | 2018 | 335 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1999 | 1593 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 1996 | 211 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2016 | 307 | 0.030 |
Why?
|
| Morbidity | 1 | 2015 | 242 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2018 | 1476 | 0.030 |
Why?
|
| Age Distribution | 1 | 2016 | 416 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 1999 | 1378 | 0.030 |
Why?
|
| Pericardial Effusion | 1 | 2015 | 72 | 0.030 |
Why?
|
| Postpartum Period | 1 | 2016 | 225 | 0.030 |
Why?
|
| Spectrometry, Mass, Fast Atom Bombardment | 1 | 1994 | 2 | 0.030 |
Why?
|
| External Fixators | 1 | 2014 | 15 | 0.030 |
Why?
|
| Adenylate Cyclase Toxin | 1 | 1994 | 3 | 0.030 |
Why?
|
| Virulence Factors, Bordetella | 1 | 1994 | 17 | 0.030 |
Why?
|
| Bone Plates | 1 | 2014 | 27 | 0.030 |
Why?
|
| Pertussis Toxin | 1 | 1994 | 21 | 0.030 |
Why?
|
| Precipitin Tests | 1 | 1994 | 136 | 0.030 |
Why?
|
| Peptides, Cyclic | 1 | 1994 | 45 | 0.030 |
Why?
|
| Immune Sera | 1 | 1994 | 83 | 0.030 |
Why?
|
| Cholera Toxin | 1 | 1994 | 43 | 0.030 |
Why?
|
| Fermentation | 1 | 1994 | 66 | 0.030 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 1994 | 34 | 0.030 |
Why?
|
| Echinocandins | 1 | 1994 | 42 | 0.030 |
Why?
|
| ROC Curve | 1 | 2016 | 572 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2000 | 660 | 0.030 |
Why?
|
| Mice, Inbred Strains | 1 | 1994 | 291 | 0.030 |
Why?
|
| Health Status Indicators | 1 | 2014 | 119 | 0.030 |
Why?
|
| Airway Obstruction | 1 | 2016 | 176 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 1999 | 2547 | 0.030 |
Why?
|
| Linear Models | 1 | 2015 | 673 | 0.030 |
Why?
|
| Homeostasis | 1 | 1998 | 686 | 0.030 |
Why?
|
| Fracture Fixation, Internal | 1 | 2014 | 89 | 0.030 |
Why?
|
| Helminth Proteins | 1 | 1994 | 103 | 0.030 |
Why?
|
| Molecular Structure | 1 | 1994 | 306 | 0.030 |
Why?
|
| Hospitals, Pediatric | 1 | 2018 | 776 | 0.030 |
Why?
|
| Candidiasis | 1 | 1994 | 108 | 0.030 |
Why?
|
| Cardiovascular Abnormalities | 1 | 2013 | 52 | 0.020 |
Why?
|
| Child Mortality | 1 | 2013 | 20 | 0.020 |
Why?
|
| Learning Curve | 1 | 2013 | 56 | 0.020 |
Why?
|
| Parents | 1 | 2020 | 1073 | 0.020 |
Why?
|
| Cost Savings | 1 | 2013 | 76 | 0.020 |
Why?
|
| Hypothalamus | 1 | 1993 | 194 | 0.020 |
Why?
|
| Pulmonary Circulation | 1 | 2013 | 114 | 0.020 |
Why?
|
| Self Efficacy | 1 | 2013 | 198 | 0.020 |
Why?
|
| Blotting, Western | 1 | 1994 | 1014 | 0.020 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 1992 | 20 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 1845 | 0.020 |
Why?
|
| Estradiol | 1 | 1993 | 476 | 0.020 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2018 | 667 | 0.020 |
Why?
|
| Heart Rate | 1 | 1994 | 567 | 0.020 |
Why?
|
| Platelet Adhesiveness | 1 | 1990 | 39 | 0.020 |
Why?
|
| Host-Parasite Interactions | 1 | 1990 | 79 | 0.020 |
Why?
|
| Platelet Aggregation | 1 | 1990 | 107 | 0.020 |
Why?
|
| Critical Care | 1 | 2015 | 661 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2013 | 790 | 0.020 |
Why?
|
| Cell Membrane Permeability | 2 | 2000 | 66 | 0.020 |
Why?
|
| Binding, Competitive | 2 | 2001 | 153 | 0.020 |
Why?
|
| Infant, Premature | 1 | 2015 | 823 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 1996 | 979 | 0.020 |
Why?
|
| Advanced Cardiac Life Support | 1 | 2009 | 17 | 0.020 |
Why?
|
| Phlebotomy | 1 | 2009 | 19 | 0.020 |
Why?
|
| Boston | 1 | 2009 | 112 | 0.020 |
Why?
|
| Spinal Puncture | 1 | 2009 | 50 | 0.020 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2016 | 620 | 0.020 |
Why?
|
| Chronic Disease | 2 | 1990 | 1187 | 0.020 |
Why?
|
| Vascular Diseases | 1 | 1990 | 149 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2009 | 105 | 0.020 |
Why?
|
| Calcium Signaling | 2 | 2001 | 240 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 1992 | 336 | 0.020 |
Why?
|
| Femur Neck | 1 | 2008 | 15 | 0.020 |
Why?
|
| Isoproterenol | 3 | 1994 | 90 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2013 | 935 | 0.020 |
Why?
|
| Bone Remodeling | 1 | 2008 | 55 | 0.020 |
Why?
|
| Spinal Fractures | 1 | 2008 | 44 | 0.020 |
Why?
|
| Lumbar Vertebrae | 1 | 2008 | 103 | 0.020 |
Why?
|
| Catheterization, Peripheral | 1 | 2009 | 124 | 0.020 |
Why?
|
| Disease Models, Animal | 3 | 1996 | 4409 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 6552 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 1136 | 0.010 |
Why?
|
| Radiation Hybrid Mapping | 1 | 2002 | 6 | 0.010 |
Why?
|
| Expressed Sequence Tags | 1 | 2002 | 79 | 0.010 |
Why?
|
| Synteny | 1 | 2002 | 75 | 0.010 |
Why?
|
| LIM Domain Proteins | 1 | 2002 | 65 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2002 | 65 | 0.010 |
Why?
|
| Thromboxane A2 | 1 | 2001 | 12 | 0.010 |
Why?
|
| Intracellular Fluid | 1 | 2001 | 20 | 0.010 |
Why?
|
| Inositol Phosphates | 1 | 2001 | 12 | 0.010 |
Why?
|
| Zebrafish Proteins | 1 | 2002 | 121 | 0.010 |
Why?
|
| Cross-Linking Reagents | 1 | 2001 | 50 | 0.010 |
Why?
|
| Dimerization | 1 | 2001 | 135 | 0.010 |
Why?
|
| Acetates | 1 | 2001 | 80 | 0.010 |
Why?
|
| Oligopeptides | 1 | 2001 | 115 | 0.010 |
Why?
|
| Cytoskeletal Proteins | 1 | 2002 | 273 | 0.010 |
Why?
|
| Cricetinae | 1 | 2001 | 365 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2001 | 231 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2002 | 749 | 0.010 |
Why?
|
| Serotonin | 1 | 2001 | 204 | 0.010 |
Why?
|
| Mammals | 1 | 2001 | 250 | 0.010 |
Why?
|
| Ligands | 1 | 2001 | 477 | 0.010 |
Why?
|
| Carbohydrate Conformation | 1 | 2000 | 15 | 0.010 |
Why?
|
| Spodoptera | 1 | 1999 | 28 | 0.010 |
Why?
|
| Muscle Proteins | 1 | 2002 | 397 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2001 | 799 | 0.010 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2001 | 266 | 0.010 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2000 | 158 | 0.010 |
Why?
|
| Binding Sites | 1 | 2001 | 1187 | 0.010 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2000 | 277 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2000 | 985 | 0.010 |
Why?
|
| Models, Structural | 1 | 1997 | 43 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2002 | 1011 | 0.010 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2000 | 810 | 0.010 |
Why?
|
| Models, Neurological | 1 | 1997 | 182 | 0.010 |
Why?
|
| Cattle | 1 | 1997 | 536 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1999 | 1293 | 0.010 |
Why?
|
| Microscopy, Video | 1 | 1996 | 19 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2000 | 1538 | 0.010 |
Why?
|
| Spasm | 1 | 1996 | 46 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2001 | 987 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1996 | 307 | 0.010 |
Why?
|
| Guanylyl Imidodiphosphate | 1 | 1994 | 2 | 0.010 |
Why?
|
| Receptors, Adrenergic, alpha | 1 | 1994 | 5 | 0.010 |
Why?
|
| Uncoupling Agents | 1 | 1993 | 5 | 0.010 |
Why?
|
| Colforsin | 1 | 1993 | 45 | 0.010 |
Why?
|
| Guanosine Triphosphate | 1 | 1993 | 38 | 0.010 |
Why?
|
| Preoptic Area | 1 | 1993 | 10 | 0.010 |
Why?
|
| Norepinephrine | 1 | 1994 | 152 | 0.010 |
Why?
|
| Ovariectomy | 1 | 1993 | 166 | 0.010 |
Why?
|
| Temperature | 1 | 1994 | 282 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1994 | 420 | 0.010 |
Why?
|
| Contraindications | 1 | 1992 | 75 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 1993 | 581 | 0.010 |
Why?
|
| Liver | 1 | 2000 | 1764 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 1994 | 588 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1993 | 1128 | 0.010 |
Why?
|
| Thromboxane B2 | 1 | 1990 | 17 | 0.010 |
Why?
|
| Epoprostenol | 1 | 1990 | 42 | 0.010 |
Why?
|
| Blood Transfusion | 1 | 1992 | 286 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 1994 | 1014 | 0.010 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1990 | 125 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 1989 | 109 | 0.000 |
Why?
|
| Nervous System Diseases | 1 | 1992 | 393 | 0.000 |
Why?
|
| Fibrosis | 1 | 1989 | 398 | 0.000 |
Why?
|
| Blood Platelets | 1 | 1990 | 312 | 0.000 |
Why?
|
| Double-Blind Method | 1 | 1989 | 1574 | 0.000 |
Why?
|